
Please try another search
WASHINGTON (Reuters) - The U.S. Federal Trade Commission has given Germany's Fresenius Medical Care AG and U.S. home dialysis equipment maker NxStage Medical Inc antitrust approval for their merger, the agency said on Tuesday.
To win approval for the $2 billion deal, the companies agreed to sell NxStage's bloodline tubing set business, the agency said. Fresenius and NxStage together dominate the market for the single-use plastic tubes used during dialysis, the agency said.
The five FTC commissioners split along party lines in voting on whether to approve the merger. The three Republicans, Joseph Simons, Noah Phillips and Christine Wilson, voted "yes," while Democrats Rohit Chopra and Rebecca Slaughter dissented.
A spokesman for Fresenius was not available for comment outside of European business hours.
Fresenius and rival DaVita Inc dominate the U.S. market for dialysis clinics. Fresenius, which has 2,200 U.S. dialysis clinics, struck the deal to buy NxStage in August 2017 as a way for it to move into cheaper home dialysis. It has served 190,000 U.S. patients, according to its website.
Simons and the Republican commissioners defended the settlement by arguing that since most patients cannot use in-home dialysis, the two services do not compete against each other, among other reasons.
Chopra and Slaughter, in separate statements, noted that the clinic dialysis market was already concentrated and that the merger could lead to higher prices for people with kidney ailments.
(Reuters) - Apple Inc (NASDAQ:AAPL) has told some of its contract manufacturers that it wants to increase production outside China, the Wall Street Journal reported, citing people...
By Terje Solsvik OSLO (Reuters) - Russia's Gazprom (MCX:GAZP) on Saturday halted gas exports to neighbouring Finland, in the latest escalation of an energy payments dispute with...
By Joey Roulette and Steve Gorman CAPE CANAVERAL, Fla. (Reuters) - Boeing (NYSE:BA)'s new Starliner crew capsule docked for the first time with the International Space Station...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.